Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
Get 40% Off
/Free Sign Up
 0
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list
Close

Plus Therapeutics Inc (PSTV)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Plus Therapeutics's earnings

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
1.760 +0.020    +1.15%
13:31:00 - Real-time Cboe. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
  • Volume: 6,190
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 1.740 - 1.857
Plus Therapeutics 1.760 +0.020 +1.15%

PSTV Balance Sheet

 
Featured here, the Balance Sheet for Plus Therapeutics Inc, which summarizes the company's financial position including assets, liabilities and shareholder equity for each of the latest 4 period ending dates (either quarterly or annually).
AnnualQuarterly
InvestingPro Advanced Balance Sheet
Collapse All
Period Ending: 2023
31/12
 2023
30/09
 2023
30/06
 2023
31/03
Total Current Assets 9.83 11.58 12.36 13.63
Cash and Short Term Investments 8.55 11.01 10.9 12.72
Cash - - - -
Cash & Equivalents 8.55 11.01 10.9 12.72
Short Term Investments - - - -
Total Receivables, Net - 0.091 0.718 -
Accounts Receivables - Trade, Net - 0.091 0.718 -
Total Inventory - - - -
Prepaid Expenses 1.28 0.487 0.751 0.906
Other Current Assets, Total - - - -
Total Assets 11.39 13.28 14.2 15.64
Property/Plant/Equipment, Total - Net 1.11 1.24 1.38 1.55
Property/Plant/Equipment, Total - Gross 3.64 - - -
Accumulated Depreciation, Total -2.54 - - -
Goodwill, Net 0.372 0.372 0.372 0.372
Intangibles, Net 0.042 0.049 0.064 0.079
Long Term Investments - - - -
Note Receivable - Long Term - - - -
Other Long Term Assets, Total 0.032 0.032 0.012 0.012
Other Assets, Total - -0.091 -0.718 -
Total Current Liabilities 10.73 10.54 11.4 12.8
Accounts Payable 4.76 6.07 6.58 6.5
Payable/Accrued - - - -
Accrued Expenses 1.87 - - -
Notes Payable/Short Term Debt - - - -
Current Port. of LT Debt/Capital Leases 4.1 4.46 4.82 5.16
Other Current liabilities, Total - - - 1.14
Total Liabilities 12.74 10.66 11.54 12.96
Total Long Term Debt - - - -
Long Term Debt - - - -
Capital Lease Obligations - - - -
Deferred Income Tax - - - -
Minority Interest - - - -
Other Liabilities, Total -1.97 -4.23 -4.57 -4.89
Total Equity -1.35 2.62 2.66 2.68
Redeemable Preferred Stock, Total - - - -
Preferred Stock - Non Redeemable, Net - - - -
Common Stock, Total 0.005 0.005 0.003 0.036
Additional Paid-In Capital 479.27 479.31 476.13 474.63
Retained Earnings (Accumulated Deficit) -480.5 -476.69 -473.47 -471.99
Treasury Stock - Common -0.126 - - -
ESOP Debt Guarantee - - - -
Unrealized Gain (Loss) - - - -
Other Equity, Total - - - -
Total Liabilities & Shareholders' Equity 11.39 13.28 14.2 15.64
Total Common Shares Outstanding 4.44 4.52 2.88 2.41
Total Preferred Shares Outstanding - - - -
* In Millions of USD (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on the balance sheet, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

PSTV Comments

Write your thoughts about Plus Therapeutics Inc
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Chiaretto Calo
Chiaretto Calo Nov 14, 2023 6:32AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
According to analysts, PSTV stock is rated as a "Strong Buy." The average 12-month stock price forecast is $10.00, representing a substantial increase of over 525% from the current price​​​​​​. Innovative Drug Development: Plus Therapeutics focuses on developing treatments for cancer and other diseases. Their lead drug candidate, Rhenium-186Re obisbemeda, targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. They are also working on other promising treatments for solid organ cancers​​. FDA Orphan Drug Designation: The company recently received U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the treatment of breast cancer with leptomeningeal metastases. This designation can provide certain benefits, including market exclusivity upon approval, assistance in clinical study design, tax credits, and exemption from FDA user fees​​. Share Repurchase Program: Plus Therapeutics announced a share repurchase program, indicating confidence in their financial stability and future prospects​​. Clinical Trial Progress: The company has been making progress in its clinical trials. For instance, they completed dosing in Cohort 4 of the ReSPECT-LM Phase 1 Clinical Trial of Rhenium (186Re) Obisbemeda in Leptomeningeal Metastases and plan to move into the next cohort following safety reviews​​​​.
Reply
0 0
Report
Nash Purswani
Nash Purswani Dec 07, 2022 8:58AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Can we file a case against all these analysts who hv giving fake hopes
Reply
0 0
Report
Péter Dovák
Péter Dovák Aug 18, 2022 6:25PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
wondering if it hits 2+
Reply
1 0
Report
Nash Purswani
Nash Purswani Aug 05, 2021 12:20PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Zero sales but everyone says strong buy - always confused with this Co but stuck n feels like slow quiksand
Reply
0 0
Report
Dragan Soldat
Dragan Soldat Aug 05, 2021 12:20PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Like others they are expecting discovery of a candidate and then boom It happens but rare
Reply
0 0
Report
Nash Purswani
Nash Purswani Aug 05, 2021 12:20PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
My thoughts also
Reply
0 0
Report
Pochette Million
Pochette Million Apr 15, 2020 11:25PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Its a very strong buy
Reply
3 0
Report
En Game
En Game Apr 15, 2020 11:25PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
I guess its an even stronger buy today
Reply
0 0
Report
victor cruz
victor cruz Nov 14, 2019 4:43PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Its merging from the ashes now.
Reply
3 0
Report
Scott Wallace
Scott Wallace Sep 23, 2019 4:05PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Really what happened????
Reply
0 0
Report
Sarika Ramonda
Sarika Ramonda Sep 23, 2019 4:05PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
$PSTV Plus Therapeutics, Inc. Announces Pricing Of $15 Million Underwritten Public OfferingThe Series U Warrants have an exercise price of $5.00 per share
Reply
1 0
Report
Jack Wood
Jack Wood Sep 23, 2019 4:05PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
This stupid firm offered millions of share mid-day at 5$ while stock was still trading at 10$. It just took few seconds to drop to 4$. It was unfair of them to do offering at 5$ as lots of bulls got trapped within seconds.
Reply
1 0
Report
Roland Jambrich
Roland Jambrich Sep 23, 2019 3:25PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
After 8 yesterday, first 16, then 3,56 today? What's going on here?
Reply
0 0
Report
andrea ciotoli
andrea ciotoli Aug 22, 2019 12:54PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
1:50
Reply
0 0
Report
Nash Purswani
Nash Purswani Aug 16, 2019 11:29PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
anyone holding the cytori warrants and know how it will be converted - same 50:1 ?
Reply
0 0
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Google
or
Sign up with Email